Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Controversies in the use of adjuvant trastuzumab (Herceptin).

Chowdhury S, Pickering L, Ellis P

Department of Medical Oncology, Guy's Hospital, London, UK.

Over-expression of the human epidermal growth factor receptor 2 (HER2) protein, amplification of the HER2 gene or both occur in 15-25% of breast cancers and are associated with aggressive tumour behaviour. Trastuzumab (Herceptin), a humanized murine monoclonal antibody against the HER2 protein, has been shown to benefit patients with HER2-positive metastatic breast cancer when administered alone or in combination with chemotherapy. When to start therapy, the duration of treatment, adjuvant chemotherapy regimens and cardiotoxicity issues are examined.

Published 20 December 2006 in J Br Menopause Soc, 12(4): 172-4.
Full-text of this article is available online (may require subscription).

© 2004-2008 Herceptin Research Today. All Rights Reserved.